Key facts
- This page summarizes Mike Ouimette's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 27 Jan 2025, 18:10.
Mike Ouimette - 23 Jan 2025 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)
- Reporting relationship
- General Counsel & Corp. Sec'y
- Issuer ticker
- PLRX
- Reported as of
- 23 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 27 Jan 2025, 18:10:00 UTC
- Prior SEC filing
- 22 Jan 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jennifer Woo, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Mike Ouimette filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 27 Jan 2025.
Change
- Previous filing in this sequence was filed on 22 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PLRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +35,000
- Change %
- +50%
- Price
- $0.000000
- Shares after
- 105,544
- Date
- 23 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PLRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +70,000
- Change %
- Price
- $0.000000
- Shares after
- 70,000
- Date
- 23 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 70,000
- Exercise price
- $11.14
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
Footnote F2
1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.